Objective The purpose of the present study was to assess sluggish cognitive tempo (SCT) behavioral symptoms among pediatric survivors of acute lymphoblastic leukemia (ALL) and to determine the relationship of these behaviors with cognitive late effects. Methods ALL survivors \((n = 80)\) and a sibling control group \((n = 19)\) were administered intelligence (IQ) testing, achievement testing and SCT behavioral items. Group differences (patients vs. siblings) were examined on the SCT behaviors and partial correlations were conducted to explore the relationship of the SCT behaviors with IQ and achievement, while controlling for age at treatment and time since treatment. Results ALL survivors exhibited significantly more SCT symptoms than the sibling control group and increased SCT symptoms were associated with lower IQ and achievement scores. Conclusions ALL survivors are vulnerable to SCT symptoms and these behaviors are associated with cognitive late effects. SCT symptoms may represent a behavioral component of cognitive late effects.

Key words academic achievement; ADHD; behavior problems; leukemia.

Leukemia is the most common form of childhood cancer, comprising 30% of new diagnoses (Pui & Evans, 1998). Although there are different subtypes of leukemia that vary in their histological mechanisms and chronicity, the most common form found in children is acute lymphoblastic leukemia (ALL). ALL is a cancer of the white blood cells, or lymphoid cells, that work to protect the body from infection (National Cancer Institute, 2002). During the 1960s, the 5-year survival rate for children diagnosed with ALL was <5% (National Cancer Institute, 2002). The dismal prognosis was due not to the primary disease itself, but to metastatic spread into the central nervous system. However, with substantial improvements in available treatments the survival rate has now increased to 85%. The most common treatment regimens for children diagnosed with ALL include prophylactic whole brain and spinal irradiation (CRT) and chemotherapy administered directly into the central nervous system (intrathecal chemotherapy; IT) to prevent metastasis (Pui & Evans, 1998).

Though successful in reducing meningeal relapse, prophylactic therapy has some marked drawbacks. In particular, intellectual (IQ) and academic declines have consistently been documented among ALL survivors, with younger age at treatment and time since treatment identified as significant risk factors (Anderson, Godber, Smibert & Ekert, 1997; Espy et al., 2001; Mulhern et al., 1987). The cognitive deficits are significant, with estimates of a 10 to 15 point drop in intellectual and academic functioning over time (Anderson et al., 1997; Cousens, Waters, Said & Stevens, 1988). Some evidence suggests that these deficits are at least partially attributable to impairments in more basic cognitive skills including attention, processing speed, and working memory (Schatz, Kramer, Ablin & Matthey, 2000).
In working clinically with survivors of childhood ALL, there are significant similarities with the subset of children with attention deficit hyperactivity disorder (ADHD) described in the literature as exhibiting a sluggish cognitive tempo (SCT). ADHD patients with SCT behavioral symptoms are described as lethargic, always daydreaming, frequently staring, and unorganized (Barkley, DuPaul, & McMurray, 1990; Carlson & Mann, 2002; Hartman, Willcutt, Rhee, & Pennington, 2004; McBurnett, Pfiffner, & Frick, 2001). These children also have documented cognitive and achievement deficits. It may be that SCT behavioral symptoms are not unique to ADHD, but instead exist among other pediatric populations including survivors of ALL.

Therefore, the purpose of the present study was to be the first to assess SCT behavioral symptoms among survivors of ALL and to determine the association of these behaviors with cognitive late effects. It was predicted that (a) ALL patients would exhibit more SCT symptoms than expected in a group of sibling control subjects and that (b) SCT behavioral symptoms would be associated with lower intelligence scores and poorer academic achievement.

**Method**

**Participants**

The nature of the present study was retrospective and the project was granted approval by the Institutional Review Board at St Jude Children’s Research Hospital (SJCRH). Patients were considered for the present study from a larger cohort participating in screening for National Cancer Institute (NCI) funded investigation of the effectiveness of methylphenidate in treating the cognitive late effects observed among child cancer survivors (Principal Investigator: R.K. Mulhern). All patients with histologically diagnosed ALL and who were 1-year postcompletion of treatment with no signs of progressive disease, or were a sibling of an ALL patient, were approached for screening. Exclusion criteria included previous diagnoses of depression, anxiety, ADHD, Tourette’s syndrome, substance abuse, or uncontrolled seizure disorder. Those excluded did not participate in the screening testing. Parents or legal guardians who were of legal age gave written informed consent and child participants gave written assent. Since patients for the present study were drawn from the screening pool of the NCI study, no patients were receiving psychotropic medication at the time of the investigation and no patients were previously treated for ADHD.

**Patient Group (n = 80)**

Patients enrolled in the current investigation had a mean age at the time of treatment of 3.8 years (SD = 2.3; range = 6 months to 11 years). There were 43 males (53.8%) and 37 females (46.3%). Seventy-four patients were Caucasian (92.5%), five were African American (6.3%), and one was of Hispanic decent (1.3%). Thirteen patients (16.3%) received whole-brain CRT and 67 (83.8%) patients were treated with chemotherapy alone.

**Sibling Control Group (n = 19)**

Among the sibling group, there were 10 males (52.6%) and 9 females (47.4%). Fifteen were Caucasian (78.9%), one was African American (5.3%), none were of Hispanic decent (0%), and three were of “other” decent (15.8%). No statistically significant differences were found between the ALL survivors and siblings on gender ($\chi^2 = 0.018$; ns). Although parametric statistical analyses could not be conducted on ethnicity due to asymmetrical data (no siblings of Hispanic decent), examination of descriptive data suggest relative similarity in ethnic representation between groups.

**Psychological Evaluation**

The psychological evaluation data for the current investigation was obtained from the screening phase of the parent NCI study; thus, patients and siblings evaluated at this time point were not required to exhibit attention problems nor had they started on the methylphenidate drug trial. At the time of testing, patients were a mean of 12.4-years old (SD = 3.3; Range = 6.6 to 18.2 years) and were 6.0 years since the completion of treatment (SD = 1.4 to 13.8 years). Siblings were a mean of 12.6-years old (SD = 3.6; Range = 6.8 to 18.6 years) at the time of testing. No statistically significant difference was found between patients and siblings on age at the time of testing ($t$ (97) = 0.21; ns). Patients and siblings received measures of SCT, intelligence, and academic achievement.

The SCT was assessed using the Child Behavior Checklist (Achenbach, 1991; CBCL). Recent studies have identified behavioral items consistent with SCT (Carlson & Mann, 2002; Hartman et al., 2004). Specifically, Hartman and colleagues (2004) identified five items from the CBCL that loaded onto the SCT factor in exploratory factor analyses and described these items as indicators of SCT. These five CBCL items included item 13 “confused or in a fog,” item 17 “daydreams or gets lost in his or her thoughts,” item 54 “overtired,” item 80 “stares blankly,” and item 102 “underactive, slow moving, or lacks energy.” Scores from each of these five items...
(0 = not true, 1 = sometimes true, 2 = often true) were combined to create a SCT total score (range = 0–10).

Patients were evaluated with an age-appropriate measure of intelligence using the Wechsler Intelligence Scale for Children, third edition (WISC-III; Wechsler, 1991) or the Wechsler Adult Intelligence Scale (Wechsler, 1997). All patients and siblings completed at least three subtests (information, similarities, and block design) allowing an estimation of global functioning (EIQ) to be calculated using a special short-form procedure (Sattler, 1992, p. 1034).

Patients and siblings were also evaluated with regard to academic achievement using the Wechsler Individual Achievement Test (WIAT; The Psychological Corporation, 1992). Measures of basic reading skills, reading comprehension, spelling, mathematical reasoning, and numerical operations were obtained.

Results
Prior to conducting the statistical analyses, the data set was examined for missing values and outliers. No participants were eliminated from the analyses as a result of missing data or outliers. Data were analyzed using SPSS statistical software.

Primary Analyses
Patients versus Siblings
A multivariate analysis of variance was conducted to determine group differences (patients vs. siblings) within the domains of behavior (SCT total score), intelligence (EIQ), and academic achievement (basic reading skills, reading comprehension, spelling, mathematical reasoning, and numerical operations; Table I). Results revealed that patients had significantly lower basic reading skills \( F(1,99) = 4.89, \ p = .029 \) and significantly higher SCT total scores \( F(1,99) = 5.26, \ p = .024 \). Although EIQ approached significance \( F(1,99) = 3.24, \ p = .075 \), no other significant differences were found.

Associations of SCT with Intelligence and Academic Achievement
SCT was examined in relation to both intelligence and academic achievement within the ALL patient group. Because younger age at treatment and increased time since treatment have both been associated with poorer cognitive outcome following ALL treatment, the variance associated with these variables was controlled for using partial correlations (Meadows et al., 1981). With the exception of spelling, higher scores on SCT were found to be significantly related to poorer performance on all outcome measures including EIQ \( r = -.302, \ p = .007 \), basic reading \( r = -.26, \ p = .022 \), numerical operations \( r = -.29, \ p = .01 \), reading comprehension, \( r = -.272, \ p = .016 \), and math reasoning \( r = -.364, \ p = .001 \).

Post-hoc Analyses
Previous literature has demonstrated that an interruption to the normal development of processing speed and working memory is a significant variable in cognitive deficits among pediatric patients surviving ALL (Schatz et al., 2000). In an effort to better understand the significant group differences in reading skills that occurred in the present study, we investigated whether SCT total score could be considered a mediator of reading skills. Using a simultaneous regression analysis, basic reading was significantly predicted by group (patients vs. siblings) and SCT \( F(2, 96) = 5.50, \ p = .005 \) and \( R^2 = .165 \). Consistent with a mediating model, the only significant predictor was SCT \( t = -2.42, \ p = .017 \). After statistically controlling for SCT, group was no longer found to be significantly related to basic reading skills \( p > .05 \). This suggests that group differences between patients and siblings on basic reading performance may be at least partially explained by differences in SCT total score.

Discussion
The purpose of the present study was to provide initial data regarding SCT behavioral symptoms among pediatric ALL survivors and to evaluate the relationship of the SCT symptoms with cognitive late effects. Consistent with our hypothesis, ALL patients evidenced significantly more SCT symptoms than the sibling control group. Additionally, these behaviors were related to cognitive late effects in that the presence of SCT behaviors was associated with impaired intellectual functioning and

<table>
<thead>
<tr>
<th>Test</th>
<th>ALL Patients Mean</th>
<th>SD</th>
<th>Siblings Mean</th>
<th>SD</th>
<th>F</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated IQ</td>
<td>93.06</td>
<td>18.25</td>
<td>101.37</td>
<td>17.23</td>
<td>3.25</td>
<td>.075</td>
</tr>
<tr>
<td>Basic reading</td>
<td>95.83</td>
<td>13.93</td>
<td>103.79</td>
<td>14.85</td>
<td>4.89</td>
<td>.029</td>
</tr>
<tr>
<td>Math reasoning</td>
<td>97.10</td>
<td>16.05</td>
<td>100.42</td>
<td>17.55</td>
<td>0.64</td>
<td>.428</td>
</tr>
<tr>
<td>Spelling</td>
<td>96.24</td>
<td>14.96</td>
<td>100.79</td>
<td>17.63</td>
<td>1.33</td>
<td>.252</td>
</tr>
<tr>
<td>Reading comprehension</td>
<td>97.45</td>
<td>14.15</td>
<td>102.16</td>
<td>16.38</td>
<td>1.60</td>
<td>.209</td>
</tr>
<tr>
<td>Numerical operations</td>
<td>94.24</td>
<td>17.92</td>
<td>93.26</td>
<td>16.58</td>
<td>0.05</td>
<td>.829</td>
</tr>
<tr>
<td>SCT composite score</td>
<td>1.74</td>
<td>2.15</td>
<td>0.58</td>
<td>0.90</td>
<td>5.26</td>
<td>.024</td>
</tr>
</tbody>
</table>
The lack of group differences in math and spelling ability may be attributable to the insensitivity of the WIAT in assessing subtle differences within these domains.

The observation that ALL survivors exhibit SCT symptoms is clinically meaningful and suggests that ALL survivors are vulnerable to this behavioral symptom cluster. One explanation is that the SCT symptoms represent a behavioral component of cognitive late effects that until now has been overlooked in the literature (Figure 1). Supporting this theory is the post-hoc observation that SCT symptoms mediated the relationship between group membership (patients vs. siblings) and basic reading. It also is possible that SCT is the behavioral manifestation of reduced processing speed, which has previously been shown to underlie deficits associated with cognitive late effects (Schatz et al., 2000). Monitoring SCT behaviors provide parents, caregivers, and teachers the opportunity to identify children at risk for cognitive late effects. Early screening of at-risk patients would allow for identification of those individuals who may benefit from a more thorough assessment. This model is consistent with the two-step screening-assessment model first proposed in psychiatric epidemiology and would allow for appropriate intervention planning and implementation (Simonian, 2006).

Given that this investigation is the first to examine the relationship between these cognitive and behavioral outcome variables among ALL survivors, additional research is needed. Specifically, future studies should explore the impact of radiation dosimetry (Merchant, 2006) on the manifestation of SCT symptoms. Additionally, the association of other psychosocial variables (e.g., emotional stressors, family environment, internalizing behavior problems, and community support of the family) with the SCT symptoms observed among ALL survivors need to be considered so as to provide insight into the multifaceted nature of cognitive late effects and to explore possible risk and resiliency factors. Additionally, the inclusion of multiple measures of cognitive and achievement functioning will allow a more thorough assessment of these abilities.

Several limitations of the present study should be considered when interpreting and generalizing the results. First, the present study was limited to parent report of behavior and did not utilize cross-situational assessment of behaviors. Future research should involve multiple informants (i.e., parent and teacher) to assess behavior across different environments. Additionally, examination of other cognitive, social, parenting and coping style variables within the context of a developmental model of risk, and resiliency for cognitive late effects is warranted. Future studies should also include treatment modality within the primary hypotheses to determine its etiological role in observed deficits.

This investigation is important as it the first to identify SCT behavioral symptoms among pediatric cancer survivors and to link these symptoms to cognitive late effects. These data support using the five SCT behavioral items as a marker for identifying ALL patients vulnerable to intellectual and achievement deficits, thereby enabling future researchers and clinicians to tailor inventions to ameliorate these problems in an empirically supported fashion.

Conflict of interest. None declared.

Received November 14, 2006; revisions received July 5, 2007; accepted July 17, 2007

References


